Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells

Abstract The challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T‐cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to CD19 CAR T cells. Currently, there is no approved...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yaqing Qie, Martha E. Gadd, Qing Shao, Tommy To, Andrew Liu, Shuhua Li, Rocio Rivera‐Valentin, Farah Yassine, Hemant S. Murthy, Roxana Dronca, Mohamed A. Kharfan‐Dabaja, Hong Qin, Yan Luo
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-09-01
Serie:	MedComm
Soggetti:	B‐cell malignancies BAFF‐R CAR T cells chronic lymphocytic leukemia immunotherapy
Accesso online:	https://doi.org/10.1002/mco2.716
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!